ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
33 announcements with these filters
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
Q2FY27 revenue ₹316 Cr (+30% YoY), EBITDA ₹68 Cr at 21% margin, PAT ₹40 Cr (+57%). Strategy: backward integration, high-value APIs, DMF/CEP filings, ₹280 Cr capex.
SMS Pharmaceuticals' Company Secretary Thirumalesh Tumma resigned effective November 4, 2026. Manohar Mollama has been appointed as the new Company Secretary effective November 5, 2026.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹316.1 Cr (+30.4% YoY) and net profit of ₹39.9 Cr (+57.7% YoY) for Q2 FY27.
SMS Pharmaceuticals received an Income Tax appellate order under Section 250 dismissing its appeal for AY 2018-19. The company says there is no material impact and is reviewing next steps.
SMS Pharmaceuticals disclosed that the CIT(Appeals) dismissed its appeal against a ₹7.19 Crore income tax assessment for AY 2018-19. The company is reviewing the order and expects no material impact.
SMS Pharmaceuticals received an Income Tax appellate order allowing its appeal for AY 2023-24. The outstanding tax demand of Rs.45.63 Crore, including interest, stands vacated.
SMS Pharmaceuticals has signed a loan agreement lending up to Rs.50 Crore to its 99.99%-owned subsidiary SMS Peptides. The unsecured, arm's-length facility has nil outstanding as on date.
SMS Pharmaceuticals has scheduled a board meeting for November 4, 2026, to consider Q2 FY27 unaudited results. This is a routine advance intimation.
SMS Pharmaceuticals Ltd has submitted its quarterly shareholding pattern for the period ended September 30, 2026. This is a routine regulatory compliance filing.
SMS Pharmaceuticals Limited held its 38th Annual General Meeting on September 29, 2026. Shareholders transacted business including the adoption of financial statements and declaration of dividend.
SMS Pharmaceuticals disclosed two market sell trades by Designated Person NVV Satyanarayana totalling ₹0.14 Crore. The PIT Reg 7(2) intimation involves a non-promoter designated person.
SMS Pharmaceuticals Limited has scheduled its 38th Annual General Meeting for September 29, 2026. Key agenda items include dividend declaration, management re-appointments, and approval of material related party transactions.
SMS Pharmaceuticals Limited has released its Annual Report and Notice for the 38th Annual General Meeting scheduled for September 29, 2026. The company reported FY26 revenue of ₹887 Crore.
CARE Ratings Limited has reaffirmed or revised the credit ratings for SMS Pharmaceuticals Limited's bank facilities. The review covers the company's long-term and short-term credit facilities.
SMS Pharmaceuticals Limited has rescheduled its 38th Annual General Meeting to September 29, 2026. Consequently, the record date for the FY 2025-26 dividend is revised to September 22, 2026.
N. Srilakshmi Padmini, an employee's immediate relative, purchased 3,000 equity shares of SMS Pharmaceuticals for ₹0.11 Crore via market purchase.
SMS Pharma reported Q1FY27 revenue of ₹207 Cr (+6% YoY) with stable EBITDA margins at ~20%. Strategy focuses on high-value APIs and peptide R&D.
SMS Pharmaceuticals reported Q1FY27 revenue of ₹207 crore, up 6% YoY. The board also approved a ₹50 crore loan infusion into its subsidiary, SMS Peptides.
SMS Pharmaceuticals has re-appointed Mr. Ramesh Babu Potluri as Executive Director for a 60-month term effective October 1, 2026.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹207 Cr (+5.6% YoY) and net profit of ₹20.9 Cr (+2.0% YoY) for Q1 FY27.
SMS Pharmaceuticals has scheduled a board meeting for August 1, 2026, to consider and approve the financial results for the quarter ended June 30, 2026.
SMS Pharmaceuticals updated the exchange regarding an ongoing police investigation into a prior impersonation case. One suspect has been arrested and remanded into judicial custody.
SMS Pharmaceuticals clarified the recent surge in its share volume, stating it is driven solely by market conditions. No material information has been withheld.
SMS Pharmaceuticals detected fraudulent transfers of 85,000 physical shares involving forged documents. The company filed a complaint with the Economic Offences Wing to safeguard shareholder interests.
SMS Pharma delivered FY26 revenue of ₹887cr (+13%) and PAT of ₹102cr (+47%). Strategy focuses on backward integration and high-margin API expansion.
SMS Pharma reported strong FY26 performance with PAT reaching ₹102 crore (up 48% YoY) and EBITDA margins expanding to 19%.
SMS Pharmaceuticals reported FY26 revenue of ₹886.87 Crore, a 13% YoY increase. Net profit surged 47% to ₹101.98 Crore, driven by backward integration and mix.
SMS Pharmaceuticals Limited recommended a final dividend of ₹0.4 per equity share for 2026. This distribution rewards shareholders while the AGM date remains pending.
SMS Pharmaceuticals re-appointed Annapragada & Co. as cost auditors and Adusumilli & Associates as internal auditors. Both appointments are for a twelve-month term.